PT - JOURNAL ARTICLE AU - Ma, Huan AU - Zhao, Dan AU - Zeng, Weihong AU - Yang, Yunru AU - Hu, Xiaowen AU - Zhou, Peigen AU - Weng, Jianping AU - Cheng, Linzhao AU - Zheng, Xueying AU - Jin, Tengchuan TI - Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge AID - 10.1101/2020.08.17.20175950 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.17.20175950 4099 - http://medrxiv.org/content/early/2020/08/21/2020.08.17.20175950.short 4100 - http://medrxiv.org/content/early/2020/08/21/2020.08.17.20175950.full AB - Monitoring the levels of SARS-CoV-2 specific antibodies such as IgG, M and A in COVID-19 patient is an alternative method for diagnosing SARS-CoV-2 infection and an simple way to monitor immune responses in convalescent patients and after vaccination. Here, we assessed the levels of SARS-CoV-2 RBD specific antibodies in twenty-seven COVID-19 convalescent patients over 28–99 days after hospital discharge. Almost all patient who had severe or moderate COVID-19 symptoms and a high-level of IgG during the hospitalization showed a significant reduction at revisit. The remaining patients who had a low-level IgG during hospitalization stayed low at revisit. As expected, IgM levels in almost all convalescent patients reduced significantly or stayed low at revisit. The RBD-specific IgA levels were also reduced significantly at revisit. We also attempted to estimate decline rates of virus-specific antibodies using a previously established exponential decay model of antibody kinetics after infection. The predicted days when convalescent patients’ RBD-specific IgG reaches to an undetectable level are approximately 273 days after hospital discharge, while the predicted decay times are 150 days and 108 days for IgM and IgA, respectively. This investigation and report will aid current and future studies to develope SARS-CoV-2 vaccines that are potent and long-lasting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementT.J. is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030104), National Natural Science Fund (Grant No.: 31870731 and U1732109), the Fundamental Research Funds for the Central Universities (WK2070000108). TJ is supported by a COVID-19 special task grant supported by Chinese Academy of Science Clinical Research Hospital (Hefei) with Grant No. YD2070002017. M.H. is supported by the new medical science fund of USTC (WK2070000130). JW and XY are supported by the Fundamental Research Funds for the Central Universities with Grant No. YD9110004001 and YD9110002002, respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Medical Ethical Committee of First Affiliated Hospital of USTC (approval number 2020-XG(H)-014 and 2020-XG(H)-009).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI promise that all data in this research are true and reliable